EX-10.30
from S-1/A
1 page
November 12, 2010 via Email Biocancell Therapeutics Inc. 8 Hartom St. Pob 45389 Jerusalem, Israel 91451 Attn: Uri Danon, Chief Executive Officer Re: Termination of October 19, 2010 Letter Agreement Sincerely Yours, Chardan Capital Markets, LLC
12/34/56
EX-10.28
from S-1/A
9 pages
(A) Familiarize Itself to the Extent Appropriate and Feasible With the Business, Operations, Properties, Financial Condition and Prospects of the Company, It Being Understood That Advisor Shall Be Entitled, in the Course of Such Familiarization, to Rely Upon Publicly Available Information and Such Other Information as May Be Supplied by the Company, Without Independent Investigation; (B) Conduct Road Shows to Introduce the Company to Potential Investors; (C) Advise and Assist the Company in Negotiating the Terms and Conditions of the Above Defined Transaction; Biocancell Therapeutics Inc
12/34/56
EX-10.23
from S-1/A
29 pages
Agreement Between Biocancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “Biocancell”) and Between the Fund for Medical Research, Development of Infrastructure and Health Services (Hereinafter: “The Fund”) Assaf Harofeh Fund, Zerifin 70300, Israel
12/34/56